Adjusting for Unknown Bias in Noninferiority Clinical Trials

被引:9
作者
Odem-Davis, Katherine [1 ]
Fleming, Thomas R. [2 ,3 ]
机构
[1] Univ Washington, Ctr Biomed Stat, Seattle, WA 98195 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2013年 / 5卷 / 03期
关键词
Active control; Constancy; Delta; Equivalence; Margin; NON-INFERIORITY TRIALS; DESIGN;
D O I
10.1080/19466315.2013.795910
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Evaluation of noninferiority is based on ruling out a threshold for what would constitute unacceptable loss of efficacy of an experimental treatment relative to an active comparator "Standard." This threshold, the "noninferiority margin," is often based on preservation of a percentage of Standard's effect. To obtain an estimate of this effect to be used in the development of the "noninferiority margin," data are needed from earlier trials comparing Standard to Placebo if the noninferiority trial does not have a Placebo arm. This approach often provides a biased overestimate of Standard's true effect in the setting of the current noninferiority study. We describe two commonly used noninferiority margin methods that adjust for this bias, the two-confidence interval (95-95), and the Synthesis margins. However, the added " variance inflation" adjustment made by 95-95 margin diminishes with increasing information from historical trial(s), and the Synthesis margin is based on a strong assumption that the relative bias is known. We introduce an alternative "Bias-adjusted" margin addressing vulnerabilities of each by attenuating the estimate and by accounting for uncertainty in the true level of bias. Examples and asymptotic estimates of noninferiority hypothesis rejection rates in the proportional hazards setting are used to compare methods.
引用
收藏
页码:248 / 258
页数:11
相关论文
共 50 条
  • [41] Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology
    Friede, Tim
    Stammer, Holger
    [J]. DRUG INFORMATION JOURNAL, 2010, 44 (05): : 599 - 607
  • [42] Reporting of noninferiority trials was incomplete in trial registries
    Dekkers, Olaf M.
    Soonawala, Darius
    Vandenbroucke, Jan P.
    Egger, Matthias
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (09) : 1034 - 1038
  • [43] Bayesian methods for the design and analysis of noninferiority trials
    Gamalo-Siebers, Margaret
    Gao, Aijun
    Lakshminarayanan, Mani
    Liu, Guanghan
    Natanegara, Fanni
    Railkar, Radha
    Schmidli, Heinz
    Song, Guochen
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (05) : 823 - 841
  • [44] Use of Mortality as an Endpoint in Noninferiority Trials May Lead to Ethically Problematic Conclusions
    Hersh, Andrew M.
    Walter, Robert J.
    Abberegg, Scott K.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (04) : 618 - 623
  • [45] Strength of Evidence of Noninferiority Trials with the Two Confidence Interval Method with Random Margin
    Wang, So-Young
    Kang, Seung-Ho
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (02) : 307 - 321
  • [46] Most noninferiority trials were not designed to preserve active comparator treatment effects
    Tsui, Michael
    Rehal, Sunita
    Jairath, Vipul
    Kahan, Brennan C.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019, 110 : 82 - 89
  • [47] Assessing the influence of treatment nonadherence on noninferiority trials using the tipping point approach
    Kim, Mimi
    Wang, Cuiling
    Xue, Xiaonan
    [J]. STATISTICS IN MEDICINE, 2019, 38 (04) : 650 - 659
  • [48] Statistical considerations for noninferiority/equivalence trials in vaccine development
    Wang, W. W. B.
    Mehrotra, D. V.
    Chan, I. S. F.
    Heyse, J. F.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (04) : 429 - 441
  • [49] Analysis of two binomial proportions in noninferiority confirmatory trials
    Lakkis, Hassan
    Lakkis, Andrew
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (02) : 257 - 275
  • [50] The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants
    Wangge, Grace
    Roes, Kit C. B.
    de Boer, Anthonius
    Hoes, Arno W.
    Knol, Mirjam J.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (03) : 222 - 227